Roivant Sciences (ROIV) Selling, General & Administrative (2020 - 2026)
Roivant Sciences' Selling, General & Administrative came in at $165.53 million for fiscal Q1 2027 (quarter ended Jun 30, 2026), up 23.5% from $134.02 million a year earlier and up 4.6% from the prior quarter.
Roivant Sciences (ROIV) Selling, General & Administrative (2020 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Roivant Sciences reported Selling, General & Administrative of $641.97 million, up 2.6% year-over-year; for FY2026 (ended Mar 31, 2026), it came in at $610.47 million, up 3.2% from FY2025.
- Selling, General & Administrative has increased in each of the last three fiscal years, with a five-year compound annual growth rate of 18.6% (FY2021 to FY2026).
- Going back by fiscal year, Selling, General & Administrative was $591.41 million in FY2025 (+42.1%), $416.13 million in FY2024 (+8.5%), $383.45 million in FY2023 (-50.5%) and $775.03 million in FY2022 (+198.2%).
- The five-year range for quarterly Selling, General & Administrative is -$91.55 million (fiscal Q4 2023) to $437.78 million (fiscal Q2 2022).
- Year-over-year, Selling, General & Administrative has increased for three consecutive quarters, with growth averaging 29.4% over the last eight quarters.
- The fastest year-over-year change in Selling, General & Administrative over five years came in fiscal Q2 2022 (growth of 632.8%), and the weakest in fiscal Q2 2023 (a decline of 64.0%).
- Business Quant data shows ROIV's Selling, General & Administrative at $158.25 million (Q4 2026), $175.07 million (Q3 2026) and $143.13 million (Q2 2026) in the three fiscal quarters before Q1 2027.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 3.43 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 6.43 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.63 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 2.90 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | -3.24 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | -5.65 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 1.75 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 1.92 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 3.41 Bn |
| 10 | Roivant Sciences | 25.81 Bn | 26.50 Bn | 1.16 Mn | 165.53 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 165.53 Mn |
| Mar 31, 2026 | 158.25 Mn |
| Dec 31, 2025 | 175.07 Mn |
| Sep 30, 2025 | 143.13 Mn |
| Jun 30, 2025 | 134.02 Mn |
| Mar 31, 2025 | 147.09 Mn |
| Dec 31, 2024 | 141.55 Mn |
| Sep 30, 2024 | 202.88 Mn |
| Jun 30, 2024 | 99.89 Mn |
| Mar 31, 2024 | 108.10 Mn |
| Dec 31, 2023 | 128.17 Mn |
| Sep 30, 2023 | 88.58 Mn |
| Jun 30, 2023 | 156.19 Mn |
| Mar 31, 2023 | -91.55 Mn |
| Dec 31, 2022 | 168.26 Mn |
| Sep 30, 2022 | 157.66 Mn |
| Jun 30, 2022 | 149.07 Mn |
| Mar 31, 2022 | 138.97 Mn |
| Dec 31, 2021 | 115.53 Mn |
| Sep 30, 2021 | 437.78 Mn |
Roivant Sciences Selling, General & Administrative API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=selling-general-and-administrative&ticker=ROIV&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "selling-general-and-administrative", "ticker": "ROIV", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=selling-general-and-administrative&ticker=ROIV&period=max&api_key=YOUR_API_KEY");
const data = await res.json();